Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to shield aging brains from Surgery's mental fog

NCT ID NCT07576543

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This long-term study follows older adults (65-90) who are having non-cardiac surgery to see if a combination of two drugs (dexmedetomidine and esketamine) plus a gentle brain stimulation technique (tDCS) can prevent memory and thinking problems that sometimes occur after surgery. The study will track participants for 3 months and beyond, looking at cognitive function and overall health. It aims to find a way to protect the brains of older patients during and after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexmedetomidine-esketamine combination and transcranial direct current stimulation (tDCS)
What this could lead to
If successful, this could point toward a way to prevent long-term cognitive decline in older adults after surgery, improving their quality of life.
What could go wrong
This is a follow-up of an ongoing trial, so results are not yet available. The interventions may not show benefit, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 65 to 90 years; * Preoperative Mini-Mental State Examination (MMSE) score \< 27 points, indicating possible cognitive impairment ranging from mild to moderate; * Scheduled to undergo elective non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration \> 1 hour; * Required patient-controlled intravenous analgesia (PCIA) after surgery. Exclusion Criteria: * Preoperative inability to communicate due to coma, severe dementia, endstage disease, or language impairment; * History of schizophrenia, epilepsy, Parkinson's disease, brain trauma/surgery, or myasthenia gravis; * Presence of metal implants in the intracranial or cervical region (such as cochlear implants, aneurysm clips, deep brain stimulation electrodes), or skin damage or severe skin disease on the head; * Severe cardiac dysfunction (left ventricular ejection fraction \< 30%), comorbid with sick sinus syndrome, severe bradycardia (heart rate \< 50 bpm), or second-degree or higher atrioventricular block, or implantation of a cardiac pacemaker; * Uncontrolled hyperthyroidism or pheochromocytoma; * Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (requiring dialysis), or ASA classification ≥ IV; * Allergy to dexmedetomidine or esketamine; * Participation in other clinical studies within the past 3 months; * Other conditions that are deemed unsuitable for study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Affilited Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310006, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 362011, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, 518036, China

  • Second Affilited Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310009, China

  • Xijing Hospital, Air Force Medical University

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.